Share ownership Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:57 05/12/2025 GMT			5-day change	1st Jan Change
310.90 ^CHF	+0.26%		+0.52%	+21.68%

10:34am	ROCHE HOLDINGS AG : Gets a Buy rating from UBS	ZD
12-04	Women can self-test at home for cervical cancer virus, new guidelines say	RE

Share class: Roche Holding AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	106,691,000	29,021,344 ( 27.2 %)	0	87.84 %
Stock B	1	702,562,700	681,822,598 ( 97.05 %)	13,853,005 ( 1.972 %)

Major shareholders: Roche Holding AG

Name	Equities	%	Valuation
State Street Global Advisors Ltd. 0.1509 %	1,060,435	0.1509 %	345 M CHF
Sjunde AP-fonden 0.1471 %	1,033,467	0.1471 %	336 M CHF
Baloise Asset Management AG 0.1202 %	844,239	0.1202 %	275 M CHF
Nordea Investment Management AB 0.1151 %	808,848	0.1151 %	263 M CHF
DWS CH AG 0.1106 %	777,172	0.1106 %	253 M CHF
Eurizon Capital SGR SpA 0.0987 %	693,672	0.0987 %	226 M CHF
Banque Cantonale de Genève (Investment Management) 0.082 %	576,245	0.082 %	187 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.0786 %	552,074	0.0786 %	180 M CHF
AllianceBernstein Investments Taiwan Ltd. 0.0766 %	538,120	0.0766 %	175 M CHF
Berner Kantonalbank AG (Investment Management) 0.0755 %	530,385	0.0755 %	173 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Aristotle Capital Management LLC 0.0388 %	2,178,682	0.0388 %	91 M CHF
Saratoga Research & Investment Management 0.0342 %	1,920,085	0.0342 %	80 M CHF
Boston Common Asset Management LLC 0.006557 %	368,553	0.006557 %	15 M CHF
Old National Bank (Investment Management) 0.004631 %	260,296	0.004631 %	11 M CHF
Altrius Capital Management, Inc. 0.003528 %	198,278	0.003528 %	8 M CHF
Bard Financial Services, Inc. 0.002467 %	138,650	0.002467 %	6 M CHF
Port Street Investments LLC 0.002319 %	130,352	0.002319 %	5 M CHF
AR Asset Management, Inc. 0.001922 %	108,000	0.001922 %	5 M CHF
Camissa Asset Management Pty Ltd. 0.001838 %	103,332	0.001838 %	4 M CHF
RhumbLine Advisers LP 0.001802 %	101,286	0.001802 %	4 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Hoffmann Family 64.97 %	69,318,000	64.97 %	23 674 M CHF
Melchior Oeri 3.792 %	4,045,950	3.792 %	1 382 M CHF
Maja Oeri 3.792 %	4,045,950	3.792 %	1 382 M CHF
Severin Schwan 0.2382 %	254,090	0.2382 %	87 M CHF
Towers Watson Investment Management Ltd. 0.1227 %	130,858	0.1227 %	45 M CHF
Scottish Widows Schroder Person Wealth (ACD) Ltd. 0.1082 %	115,436	0.1082 %	39 M CHF
zCapital AG 0.089 %	95,000	0.089 %	32 M CHF
Sjunde AP-fonden 0.0451 %	48,151	0.0451 %	16 M CHF
State Street Global Advisors Ltd. 0.0434 %	46,275	0.0434 %	16 M CHF
LLB Asset Management AG 0.0337 %	35,934	0.0337 %	12 M CHF
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	11.06%
Institutional	4.93%
Unknown	84.01%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	11.06%
Switzerland	1.34%
United States	1.04%
United Kingdom	0.49%
Sweden	0.29%
Germany	0.19%
Ireland	0.17%
Italy	0.16%
France	0.14%
Spain	0.14%
Luxembourg	0.12%
Norway	0.11%
Finland	0.1%
Liechtenstein	0.1%
Taiwan	0.08%
Belgium	0.07%
Canada	0.07%
New Zealand	0.05%
Portugal	0.05%
Netherlands	0.05%
Austria	0.04%
Denmark	0.03%
South Africa	0.03%
Australia	0.02%
Singapore	0.02%
Japan	0.02%
Hong Kong	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

12-06 - American Society of Hematology Meeting - Oral Presentation No:49

More about the company